February 2020

By entrusting development of its drug candidate to our expertise, a NASDAQ-listed North American company is following the lead of European and Asian businesses by choosing ETAP-Lab’s DNCB-induced atopic dermatitis mouse model.Indeed, ETAP-Lab has just signed a major contract to assess the effects of a dermatological pharmaceutical treatment currently in development.Atopic dermatitis is a common skin condition that mainly results in redness, lesions and intense itching (pruritus). For patients, it can affect everyday life severely enough to cause anxiety and